Daniel Ellis

This paper develops an mRNA-launched nanoparticle vaccine that combines protein nanoparticle and mRNA vaccine advantages, showing enhanced antibody and T cell responses in mice.

This study identifies human antibodies that broadly inhibit influenza neuraminidase by mimicking its substrate through structural convergence and water-mediated interactions.

Designed trimers matched to viral glycoprotein termini yielded tetrahedral, octahedral and icosahedral nanoparticles with cryo-EM-verified structures that display native-like HIV Env, influenza HA and RSV F.